Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial
ONCOLOGY RESEARCH AND TREATMENT（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined